Glenmark Pharma tanks 7% on BSE

PTI Mumbai | Updated on January 18, 2011 Published on January 18, 2011

Extending its losses for the fifth day on Tuesday, Glenmark Pharmaceuticals fell sharply by 7 per cent in early trade on the Bombay Stock Exchange, days after a setback in patent case against US firm Abbott Laboratories over hypertension drug Tarka.

Shares of Glenmark plunged by 7 per cent to a one-month low of Rs 302.25 on BSE in early trade. In the last four trading sessions, the stock had lost 6.9 per cent on the bourse.

The scrip saw a similar downward movement on the National Stock Exchange, where it tumbled 7 per cent to an early low of Rs 302.

A federal jury in New Jersey had rejected Glenmark’s challenge to the validity of the patent that expires in February 2015. The company will have to pay $16 million in damages to the US firm.

According to the latest order, jurors awarded $15.2 million for lost profits and $8,03,514 for higher prices that Abbott would have been able to charge had Glenmark not infringed the patent.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on January 18, 2011
This article is closed for comments.
Please Email the Editor